How Can prognosis for diabetic esrd be improved?

Seminars in Dialysis

Volumn 23, Issue 2, 2010, Pages 214-219

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Cavalli, Andrea ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; ARTIFICIAL MEMBRANE;

ARTICLE; ARTIFICIAL MEMBRANE; CATHETERIZATION; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; HUMAN; HYPOTENSION; METHODOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY; TIME; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC; PROCEDURES;

BIOCOMPATIBLE MATERIALS; CATHETERIZATION, PERIPHERAL; DIABETIC NEPHROPATHIES; HUMANS; HYPOTENSION; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; TIME FACTORS;

EID: 77953209359     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00709.x     Document Type: Article

References (43)

1. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808.
2. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997, 12:2603-2611.
3. USRDS 2004 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2004, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
4. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2009, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
5. Nelson CB, Port FK, Wolfe RA, Guire KE. The association of diabetic status, age and race to withdrawal from dialysis. J Am Soc Nephrol 1994, 4:1608-1614.
6. Foley RN, Parfrey PS. Cardiac disease in the diabetic dialysis patient. Nephrol Dial Transplant 1998, 13:1112-1113.
7. Speckman RA, Frankenfield DL, Roman SH, Eggers PW, Bedinger MR, Rocco MV, McClellan WM. Diabetes is the strongest risk factor for lower-extremity amputation in new hemodialysis patients. Diabetes Care 2004, 27:2198-2203.
8. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E. German diabetes and dialysis study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
9. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
10. Bonomini V, Vangelista A, Stefoni S. Early dialysis in renal substitutive programs. Kidney Int Suppl 1978, 8:S112-S116.
11. Korevaar JC, Jansen MA, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT. Netherlands Cooperative Study on the Adequacy of Dialysis?2. Evaluation of DOQI guidelines: early start of dialysis treatment is not associated with better health-related quality of life. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 2002, 39:108-115.
12. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002, 13:2125-2132.
13. Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006. Am J Kidney Dis 2006, 48(Suppl 1):S2-S90.
14. Ritz E, Strumpf C, Katz F, Wing AJ, Quellhorst E. Hypertension and cardiovascular risk factors in hemodialyzed diabetic patients. Hypertension 1985, 7(Suppl 11):S118-S124.
15. Locatelli F, Andrulli S, Di Filippo S, Redaelli B, Mangano S, Navino C, Ariano R, Tagliaferri M, Fidelio T, Corti M, Civardi S, Tetta C. Effect of on-line conductivity plasma ultrafiltrate kinetic modelling on cardiovascular stability of hemodialysis patients. Kidney Int 1998, 53:1052-1060.
16. Parker TF, Laird NM, Lowrie EG. Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality, and patient withdrawal. Kidney Int Suppl 1983, 13:S42-S49.
17. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM. The dose of hemodialysis and patient mortality. Kidney Int 1996, 50:550-556.
18. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.
19. Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of " dose-targeting bias." J Am Soc Nephrol 2005, 16:3371-3380.
20. Locatelli F. Dose of dialysis, convection and haemodialysis patients outcome-what the HEMO study doesn't tell us: the European viewpoint. Nephrol Dial Transplant 2003, 18:1061-1065.
21. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis in patients. J Am Soc Nephrol 2002, 13:1061-1066.
22. Szczech LA, Lowrie EG, Li Z, Lew NL, Lazarus JM, Owen WF. Changing hemodialysis thresholds for optimal survival. Kidney Int 2001, 59:738-745.
23. Charra B, Terrat JC, Vanel T, Chazot C, Jean G, Hurot JM, Lorriaux C. Long thrice weekly hemodialysis: the Tassin experience. Int J Artif Organs 2004, 27:265-283.
24. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006, 69:1222-1228.
25. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006, 69:1229-1236.
26. Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999, 14:2835-2840.
27. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 2003, 42:13-17.
28. Fagugli RM, Pasini P, Pasticci F, Ciao G, Cicconi B, Buoncristiani U. Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: a comparative study. J Nephrol 2006, 19:77-83.
29. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005, 67:1500-1508.
30. Chan C, Floras JS, Miller JA, Pierratos A. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 2002, 17:1518-1521.
31. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007, 298:1291-1299.
32. Kjellstrand CM, Buoncristiani U, Ting G, Traeger J, Piccoli GB, Sibai-Galland R, Young BA, Blagg CR. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant 2008, 23:3283-3289.
33. Woods JD, Port FK, Stannard D, Blagg CR, Held PJ. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int 1996, 49:1464-1470.
34. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001, 37:276-286.
35. Chauveau P, Nguyen H, Combe C, Chêne G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005, 45:565-571.
36. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008, 19:863-870.
37. Locatelli F, Martin-Malo A, Hannedouche TA, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009, 20:645-654.
38. Krane V, Krieter DH, Olschewski M, März W, Mann JF, Ritz E, Wanner C. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007, 49:267-275.
39. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006, 69:2087-2093.
40. Konner K, Hulbert-Shearon TE, Roys EC, Port FK. Tailoring the initial vascular access for dialysis patients. Kidney Int 2002, 62:329-338.
41. Maiorca R, Vonesh EF, Cavalli P, De Vecchi A, Giangrande A, La Greca G, Scarpioni LL, Bragantini L, Cancarini GC, Cantaluppi A, Castelnovo C, Castiglioni A, Poisetti PG, Viglino G. A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991, 11:118-127.
42. Rodriguez JA, Cleries M, Vela E. Diabetic patients on renal replacement therapy: Analysis of Catalan Registry data. Renal Registry Committee. Nephrol Dial Transplant 1997, 12:2501-2509.
43. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001, 12:2411-2417.